Mesoblast (MESO) Total Current Liabilities (2014 - 2026)
Mesoblast (MESO) posted Total Current Liabilities of $128.1 million for Q4 2025, up 24.79% sequentially from $102.6 million in Q2 2025, and up 76.04% YoY from $72.8 million in Q4 2024.
Analysis
Mesoblast (MESO) Total Current Liabilities (2014 - 2026) Analysis & Trends
Mesoblast has reported Total Current Liabilities for 11 years, with the latest figure at $128.1 million in Q4 2025.
- Quarterly Total Current Liabilities rose 76.04% year-over-year to $128.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $128.1 million (up 76.04% YoY) and the FY2025 annual result came in at $102.6 million, up 40.12% from the prior year.
- Total Current Liabilities rose to $128.1 million in Q4 2025 per MESO's latest filing, from $102.6 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $128.1 million in Q4 2025 and troughed at $31.4 million in Q4 2023.
- A 5-year average of $70.3 million and a median of $58.0 million in 2021 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities plunged 47.47% in 2022, then jumped 131.93% in 2024.
- Over 5 years, Total Current Liabilities stood at $58.0 million in 2021, then dropped by 5.83% to $54.6 million in 2022, then plunged by 42.53% to $31.4 million in 2023, then surged by 131.93% to $72.8 million in 2024, then surged by 76.04% to $128.1 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $128.1 million, $102.6 million, and $72.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 81.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 81.11 Mn |
| Dec 31, 2025 | 128.07 Mn |
| Jun 30, 2025 | 102.63 Mn |
| Dec 31, 2024 | 72.75 Mn |
| Jun 30, 2024 | 73.24 Mn |
| Dec 31, 2023 | 31.37 Mn |
| Jun 30, 2023 | 41.98 Mn |
| Mar 31, 2023 | 53.92 Mn |
| Dec 31, 2022 | 54.58 Mn |
| Sep 30, 2022 | 48.80 Mn |
| Jun 30, 2022 | 51.37 Mn |
| Mar 31, 2022 | 52.19 Mn |
| Dec 31, 2021 | 57.95 Mn |
| Sep 30, 2021 | 92.90 Mn |
| Jun 30, 2021 | 94.27 Mn |
| Mar 31, 2021 | 98.55 Mn |
| Dec 31, 2020 | 91.04 Mn |
| Sep 30, 2020 | 87.70 Mn |
| Jun 30, 2020 | 90.14 Mn |
| Mar 31, 2020 | 76.69 Mn |